Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
HLX26
i
Other names:
HLX26
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Fosun Pharma
Drug class:
LAG-3 inhibitor
Related drugs:
‹
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
IBI110 (2)
MK-4280 (2)
REGN3767 (2)
FS118 (1)
BMS-986016 (1)
ABL501 (0)
CB213 (0)
EMB-02 (0)
GB266 (0)
GLS-012 (0)
IBI-323 (0)
INCA32459 (0)
SHR-1802 (0)
Sym022 (0)
TNRX-257 (0)
ZGGS15 (0)
LBL-007 (0)
XmAb22841 (0)
TSR-033 (0)
MK-4280A (0)
LAG525 (0)
BI 754111 (0)
RG6139 (0)
INCAGN2385 (0)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
IBI110 (2)
MK-4280 (2)
REGN3767 (2)
FS118 (1)
BMS-986016 (1)
ABL501 (0)
CB213 (0)
EMB-02 (0)
GB266 (0)
GLS-012 (0)
IBI-323 (0)
INCA32459 (0)
SHR-1802 (0)
Sym022 (0)
TNRX-257 (0)
ZGGS15 (0)
LBL-007 (0)
XmAb22841 (0)
TSR-033 (0)
MK-4280A (0)
LAG525 (0)
BI 754111 (0)
RG6139 (0)
INCAGN2385 (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients (NCT05787613)
Phase 2
Shanghai Henlius Biotech
Shanghai Henlius Biotech
Recruiting
Phase 2
Shanghai Henlius Biotech
Recruiting
Last update posted :
02/22/2024
Initiation :
07/10/2023
Primary completion :
07/01/2025
Completion :
07/01/2027
PD-L1 • ROS1 • LAG3
|
PD-L1 expression • ROS1 rearrangement • LAG3 expression
|
carboplatin • albumin-bound paclitaxel • pemetrexed • Hetronifly (serplulimab) • HLX26
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor (NCT05400265)
Phase 1
Shanghai Henlius Biotech
Shanghai Henlius Biotech
Completed
Phase 1
Shanghai Henlius Biotech
Completed
Last update posted :
02/06/2024
Initiation :
07/26/2022
Primary completion :
08/31/2023
Completion :
01/31/2024
ROS1
|
Hetronifly (serplulimab) • HLX26
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC (NCT05584137)
Phase 2
Shanghai Henlius Biotech
Shanghai Henlius Biotech
Suspended
Phase 2
Shanghai Henlius Biotech
Suspended
Last update posted :
08/11/2023
Initiation :
06/15/2023
Primary completion :
08/30/2024
Completion :
04/30/2026
KRAS • BRAF
|
BRAF mutation • KRAS wild-type • RAS wild-type
|
Hetronifly (serplulimab) • HLX26
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login